ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

But 'Unique Side Effects' A Concern

 
• By Kevin Grogan
Lung Cancer
Pfizer pushing in ALK-Positive lung cancer space • Source: Shutterstock

More from Clinical Trials

More from R&D